<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707070</url>
  </required_header>
  <id_info>
    <org_study_id>Gisondi 2</org_study_id>
    <secondary_id>No grants were received</secondary_id>
    <nct_id>NCT00707070</nct_id>
  </id_info>
  <brief_title>Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis</brief_title>
  <acronym>CobAcE</acronym>
  <official_title>Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a phase IV multicentric, placebo-controlled, clinical trial investigating the efficacy
      and safety of acitretin combined to efalizumab in the therapy of chronic plaque psoriasis.
      PASI 75 at week 24 will be the primary end point. PASI 75 at week 12, and PASI 50 at week 24
      will be the secondary end points. Safety measures will be the monitoring of serum parameters
      including AST; ALT; gammaGT; creatinine; cholesterol and triglycerides.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI 75 and PASI 50 at week 24 Physician Global Assessment</measure>
    <time_frame>week 12 and 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SKINDEX 29 at week 24 and AST, ALT, cholesterol, triglycerides at week 12 and week 24</measure>
    <time_frame>week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>efalizumab 1 mg/Kg/week subcutaneous plus oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efalizumab plus placebo</intervention_name>
    <description>1 mg/kg/week subcutaneous for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efalizumab plus acitretin</intervention_name>
    <description>1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18-70

          -  Women in postmenopausal

          -  Moderate to severe chronic plaque psoriasis in patients with contraindication,
             intolerance or non responsive to cyclosporine, methotrexate or PUVA

          -  PASI &gt; 10 e/o BSA (Body Surface Area) &gt; 10

        Exclusion Criteria:

          -  Drug induced psoriasis

          -  Pustular or erythrodermic psoriasis

          -  Fertile women

          -  Pregnancy or lactation

          -  cholesterol &gt; 230mg/dL e triglyceride &gt; 200 mg/dL

          -  Known intolerance to efalizumab and acitretin

          -  Serious infection at enrollement

          -  History of previous neoplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giampiero Girolomoni</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Verona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giampiero Girolomoni, Prof</last_name>
    <phone>39-045-812-2547</phone>
    <phone_ext>0039</phone_ext>
    <email>giampiero.girolomoni@univr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univeristy Hospital</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo Gisondi, MD</last_name>
      <phone>45-812-2547</phone>
      <phone_ext>0039</phone_ext>
      <email>paolo.gisondi@univr.it</email>
    </contact>
    <investigator>
      <last_name>Micol Del Giglio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Gisondi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giampiero Girolomoni, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gisondi P, Girolomoni G. Combination of efalizumab and acitretin in chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2008 Feb;22(2):247-8. doi: 10.1111/j.1468-3083.2007.02303.x.</citation>
    <PMID>18211428</PMID>
  </reference>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2008</study_first_posted>
  <last_update_submitted>June 27, 2008</last_update_submitted>
  <last_update_submitted_qc>June 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Giampiero Girolomoni</name_title>
    <organization>University of Verona</organization>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>acitretin</keyword>
  <keyword>efalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Acitretin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

